Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

n reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section in Genzyme's Quarterly Report on Form 10-Q for the period ended March 31, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise these statements.

Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800- 905-4369 within the United States or 1-703-797-1866 outside the United States.

    Media Contact:       Investor Contact:

    Dan Quinn            Catie Forte

    (617) 768-6849       (617) 768-6881

CONTACT: media, Dan Quinn, 617-768-6849, or investors, Catie Forte,617-768-6881

Web site: http://www.genzyme.com//

Company News On-Call: http://www.prnewswire.com/comp/113803.html /

Ticker Symbol: (NASDAQ-NMS:GENZ)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:1/23/2015)... 2015  Mallinckrodt plc (NYSE: MNK ) announced ... share repurchase program. The open-ended authorization permits the company ... ordinary shares. "Funding additional initiatives and ... we continue to pursue a range of focused growth ...
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
(Date:1/22/2015)... a privately held medical device company, announced today that ... ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to sell ... cancer in Japan . ViewRay,s technology, ... only MRI-guided radiation therapy system that images and treats ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... Furthering its commitment to provide patients ... B. Braun Medical Inc. (B. Braun) today announced ... Amerinet Inc., a leading national healthcare group purchasing organization. ... ) , Effective November 1, the new five-year agreement ...
... NEW YORK, Oct. 20 Code Blue, billed as ... the body combat dehydration, replenish vital nutrients, remove harmful ... L-Alanyl-L-Glutamine from Kyowa Hakko USA in the formulation. , ... all natural powerful ingredients in Code Blue allow you ...
Cached Medicine Technology:B. Braun and Amerinet Sign to Expand Infusion Therapy Offerings 2B. Braun and Amerinet Sign to Expand Infusion Therapy Offerings 3Code Blue Recovery Drink Features Sustamine(TM) from Kyowa Hakko 2
(Date:1/22/2015)... Liberty University has received accreditation for its ... the Council for Accreditation of Counseling & Related Educational ... Center for Counseling & Family Studies , is under the ... new School of Behavioral Sciences. Prior to the formation of ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... ... software for Investigator Initiated Studies Offers Expanded Features for Compliance and Effectiveness. , ... Charlottesville, VA, San Francisco, ... their previous releases, openQ has released an expanded offering for managing Investigator Initiated Studies/ ...
... , ... Energy Beam Adds Much-Needed Weapon in Treating Brain Tumors, with Gentler Side Effects. ... (PRWEB) May 26, ... , a precise form of cancer radiation that offers potentially life-changing benefits to children ...
... ... ... University of Colorado Hospital (UCH) has announced ambitious plans to add a second inpatient tower ... $400 million, the project brings more patient beds, more emergency care and more jobs to the ...
... ... Conversation About Health Justice in Connecticut , ... New Britain, Conn. (PRWEB) May 26, 2010 -- Health Justice CT, an initiative ... residents on the issue of racial and ethnic disparities, today announced the formation of the ...
... intensify efforts to improve the health of women and ... share of deaths occur, says Dr. Philip Baker, an ... is the lead author on a G8 positioning paper ... medical experts on women and children,s health. The ...
... devices help babies survive, thrive into adulthood, study shows , ... that was typically fatal three decades ago is no longer ... allow babies to survive well into adulthood, researchers report. , ... New England Journal of Medicine compares the effectiveness of ...
Cached Medicine News:Health News:OpenQ Announces the Release of openIIS 2.5 2Health News:Proton Therapy Carries Precise, Potent Punch Against Cancers for Patients at The Children's Hospital of Philadelphia 2Health News:Proton Therapy Carries Precise, Potent Punch Against Cancers for Patients at The Children's Hospital of Philadelphia 3Health News:Proton Therapy Carries Precise, Potent Punch Against Cancers for Patients at The Children's Hospital of Philadelphia 4Health News:,University of Colorado Hospital Moving Forward with $400 Million Expansion, 2Health News:,University of Colorado Hospital Moving Forward with $400 Million Expansion, 3Health News:Health Justice CT Forms Advisory Board to Raise Awareness About Health Care Quality 2Health News:Health Justice CT Forms Advisory Board to Raise Awareness About Health Care Quality 3Health News:Progress Made Against Once-Fatal Heart Defect 2Health News:Progress Made Against Once-Fatal Heart Defect 3
LH EIA Reproductive Markers 025-BC-1031 Luteinizing Hormone...
... The procedure follows the basic principle ... is competition between an unlabeled antigen and ... binding sites of a specific antiserum . ... biotin-labelled estrone) bound to the antibody is ...
... (5-Androstene-3-0L-17-one,Androstenolone, Dehydroisoandrosterone,Transdehydroandrosterone, DHEA) is a ... mostly in its,sulfate form (DHEA-S). ... based on the competition principle ... amount of DHEA-S present in ...
... Angiotensin Converting Enzyme (ACE), also known ... (EC 3.4.15.1) with a molecular weight of ... glycoprotein shows a single polypeptide chain, a ... is present in many different cell types ...
Medicine Products: